Answers are grounded in this paper and cite their sources.
A retrospective study links HLA-DRB1*15 to severe DReSS-like inflammatory syndromes in pediatric CAR-T patients, suggesting personalized cytokine therapy may reduce risks.
Chimeric antigen receptor (CAR) T-cell therapy is associated with heterogeneous inflammatory toxicities. While cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated HLH-like syndrome (IEC-HS) are well characterized, the U.S. Food and Drug Administration recently issued a warning for drug reaction with eosinophilia and systemic symptoms (DReSS) associated with interleukin(IL)-1 and IL-6 inhibitors (IL-1i/IL-6i), agents routinely used to manage CAR-related toxicities. In non-CAR settings, HLA-DRB1*15 alleles have been linked to increased risk of DReSS following IL-1i/IL-6i exposure. The contribution of HLA haplotype to post-CAR inflammatory complications has not been reported. We hypothesized that HLA-DRB1 * 15 is associated with increased risk of severe DReSS-like inflammatory syndromes following cytokine blockade after CAR-T therapy. We performed a single-center retrospective study of pediatric patients with B-cell acute lymphoblastic leukemia treated with CAR-T cells. Variables included HLA-DRB1 typing, exposure to tocilizumab (IL-6i) and/or anakinra (IL-1i), eosinophilia, organ-specific inflammation within 90 days of cytokine blockade, shock, rash, CRS, ICANS, and laboratory markers of systemic inflammation. DReSS-like reaction features include eosinophilia, multi-organ involvement and rash temporally associated with IL-1i/IL-6i exposure. Among 21 CAR-T recipients, 8 (38%) received tocilizumab and 13 (62%) did not. No DReSS-like reactions occurred in patients not exposed to tocilizumab. Among tocilizumab-treated patients, 3/8 (38%) developed severe delayed inflammatory toxicities with DReSS-like features, including eosinophilia and multi-organ involvement (3/3 vs 0/5; p=0.018). Clinical manifestations included acute renal failure (2/3), severe hepatic injury (2/3), rash (2/3), and myocarditis with pancytopenia (1/3). Two of three affected patients carried HLA-DRB1* 15 alleles. Overall, HLA-DRB1 *15 was present in 13/21 (33%) patients; among those exposed to tocilizumab, both HLA-DRB1*15-positive patients developed DReSS-like toxicity, whereas no such reactions occurred in unexposed carriers. All three affected patients received adjunctive anakinra. These findings identify a previously unrecognized association between HLA-DRB1*15 (population prevalence ∼20%) and severe inflammatory syndromes following cytokine blockade after CAR-T therapy. This phenotype may contribute to refractory or delayed inflammatory complications, including IEC-HS. If validated, HLA-informed selection of cytokine-directed therapy, favoring short-acting IL-1 blockade over long-acting IL-6 inhibition in genetically susceptible patients, may represent a precision strategy to mitigate post-CAR toxicity.
No takes yet. Share an insight, caveat, or question.
Saper et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: